Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of C13-CAC Breath Test in PPI Resistant GERD
NCT03284177Phase 2Completed
- Sponsor
- Otsuka Pharmaceutical Co., Ltd.
- Start
- Oct 2017
- Primary completion
- Dec 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of calcium carbonate (13C) in gastroesophageal reflux disease (GERD), sponsored by Otsuka Pharmaceutical Co., Ltd. Primary endpoint: 13CO2 concentration in expired air. Started Oct 2017; status: completed.
02
Drugs
calcium carbonate (13C)
03
Conditions
gastroesophageal reflux disease (GERD)
Beyond the preview
Go deeper on NCT03284177.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03284177.